A 'Major, Major Finding' in Managing Residual Breast Cancer A 'Major, Major Finding' in Managing Residual Breast Cancer
The addition of capecitabine to standard care for HER2-negative breast cancer patients with residual invasive disease after neoadjuvant chemo and surgery improved disease-free and overall survival. Medscape Medical News
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Hematology | HER2 | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Surgery | Xeloda